623 related articles for article (PubMed ID: 26009251)
1. Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.
Kon V; Yang H; Fazio S
Arch Med Res; 2015 Jul; 46(5):379-91. PubMed ID: 26009251
[TBL] [Abstract][Full Text] [Related]
2. Importance of high-density lipoprotein quality: evidence from chronic kidney disease.
Kon V; Ikizler TA; Fazio S
Curr Opin Nephrol Hypertens; 2013 May; 22(3):259-65. PubMed ID: 23470818
[TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
4. Lipid-modifying therapy in chronic kidney disease: Pathophysiological and clinical considerations.
Heine GH; Eller K; Stadler JT; Rogacev KS; Marsche G
Pharmacol Ther; 2020 Mar; 207():107459. PubMed ID: 31863818
[TBL] [Abstract][Full Text] [Related]
5. Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.
Vaziri ND; Norris KC
Blood Purif; 2013; 35(1-3):31-6. PubMed ID: 23343544
[TBL] [Abstract][Full Text] [Related]
6. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
7. Clinical assessment and management of dyslipidemia in patients with chronic kidney disease.
Nitta K
Clin Exp Nephrol; 2012 Aug; 16(4):522-9. PubMed ID: 22722878
[TBL] [Abstract][Full Text] [Related]
8. High-Density Lipoprotein Subfractions and Their Oxidized Subfraction Particles in Patients with Chronic Kidney Disease.
Honda H; Hirano T; Ueda M; Kojima S; Mashiba S; Hayase Y; Michihata T; Shibata T
J Atheroscler Thromb; 2016; 23(1):81-94. PubMed ID: 26289085
[TBL] [Abstract][Full Text] [Related]
9. Dysfunctional high-density lipoproteins in children with chronic kidney disease.
Kaseda R; Jabs K; Hunley TE; Jones D; Bian A; Allen RM; Vickers KC; Yancey PG; Linton MF; Fazio S; Kon V
Metabolism; 2015 Feb; 64(2):263-73. PubMed ID: 25467845
[TBL] [Abstract][Full Text] [Related]
10. High-Density Lipoprotein and Low-Density Lipoprotein Subfractions in Patients with Chronic Kidney Disease.
Rysz-Gorzynska M; Gluba-Brzozka A; Banach M
Curr Vasc Pharmacol; 2017; 15(2):144-151. PubMed ID: 27697068
[TBL] [Abstract][Full Text] [Related]
11. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
Vaziri ND
J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
[TBL] [Abstract][Full Text] [Related]
12. Still a reasonable goal: Targeting cholesterol in dialysis and advanced chronic kidney disease patients.
Heine GH; Rogacev KS; Weingärtner O; Marsche G
Semin Dial; 2017 Sep; 30(5):390-394. PubMed ID: 28628255
[TBL] [Abstract][Full Text] [Related]
13. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S
Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350
[TBL] [Abstract][Full Text] [Related]
14. Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease.
Marsche G; Heine GH; Stadler JT; Holzer M
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32967334
[TBL] [Abstract][Full Text] [Related]
15. Cholesterol Metabolism in CKD.
Reiss AB; Voloshyna I; De Leon J; Miyawaki N; Mattana J
Am J Kidney Dis; 2015 Dec; 66(6):1071-82. PubMed ID: 26337134
[TBL] [Abstract][Full Text] [Related]
16. HDL in CKD-The Devil Is in the Detail.
Kronenberg F
J Am Soc Nephrol; 2018 May; 29(5):1356-1371. PubMed ID: 29472417
[TBL] [Abstract][Full Text] [Related]
17. Chronic kidney disease induced dysfunction of high density lipoprotein.
Yamamoto S; Kon V
Clin Exp Nephrol; 2014 Apr; 18(2):251-4. PubMed ID: 24018401
[TBL] [Abstract][Full Text] [Related]
18. High-density lipoprotein: structural and functional changes under uremic conditions and the therapeutic consequences.
Schuchardt M; Tölle M; van der Giet M
Handb Exp Pharmacol; 2015; 224():423-53. PubMed ID: 25522997
[TBL] [Abstract][Full Text] [Related]
19. How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL.
Averna M; Stroes E;
Atheroscler Suppl; 2017 Apr; 26():16-24. PubMed ID: 28434480
[TBL] [Abstract][Full Text] [Related]
20. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
